2-Methoxyestradiol inhibits differentiation and is cytotoxic to osteoclasts

Journal of Cellular Biochemistry

Volumn 99, Issue 2, 2006, Pages 425-434

  Maran, A ^a,d   Corny, G ^b   Oursler, M J ^a   Zhang, M ^a   Shogren, K L ^a   Yaszemski, M J ^a   Turner, R T ^c  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c OREGON STATE UNIVERSITY   (United States)

^d Mayo Clinic   (United States)

Author keywords

Apoptosis; Bone resorption; Cytokines; Estrogen metabolite

Indexed keywords

2 HYDROXYESTRADIOL; 2 METHOXYESTRADIOL; 2 METHOXYESTRONE; COLONY STIMULATING FACTOR 1; CYTOKINE; DRUG ANALOG; DRUG METABOLITE; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; LIGAND; LYMPHOTOXIN BETA; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN ANTIBODY;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE DISEASE; BONE MARROW CELL; BONE METASTASIS; CELL COUNT; CELL CULTURE; CELL DEATH; CELL DIFFERENTIATION; CELL LINE; CELL STRAIN RAW 264.7; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; FEMALE; GENE EXPRESSION; LIGAND BINDING; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SPLEEN CELL; STROMA CELL; TUMOR CELL;

ANIMALS; APOPTOSIS; BONE RESORPTION; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; CELLS, CULTURED; CYTOKINES; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; LYMPHOTOXIN-ALPHA; LYMPHOTOXIN-BETA; MEMBRANE PROTEINS; MICE; OSTEOCLASTS; RATS; RNA, MESSENGER;

EID: 33748932483     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20924     Document Type: Article

References (52)

1. Aitken JM, Hart DM, Lindsay R. 1973. Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy. Br Med J 3:515-518.
2. Attalla H, Westberg JA, Andersson LC, Adlercreutz H, Makela TP. 1998. 2-Methoxyestradiol-induced phosphorylation of Bcl-2: Uncoupling from JNK/SAPK activation. Biochem Biophys Res Commun 247:616-619.
3. Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ. 2001. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28:465-473.
4. Chambers TJ. 2000. Regulation of the differentiation and function of osteoclasts. J Pathol 192:4-13.
5. Chomczynski P, Sacchi N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159.
6. D'Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E. 1994. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA 91:3964-3968.
7. Djavaheri-Mergny M, Wietzerbin J, Rouillard D, Besancon F. 2003. TNFalpha potentiates 2-methoxyestradiol-induced mitochondrial death pathway. Ann NY Acad Sci 1010:159-162.
8. Evans GL, Morey-Holton E, Turner RT. 1998. Spaceflight has compartment- and gene-specific effects on mRNA levels for bone matrix proteins in rat femur. J Appl Physiol 84:2132-2137.
9. Fleming RM. 2003. Do women taking hormone replacement therapy (HRT) have a higher incidence of breast cancer than women who do not? Integr Cancer Ther 2:235-237.
10. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L. 1994. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368:237-239.
11. Frith JC, Monkkonen J, Blackburn GM, Russell RG, Rogers MJ. 1997. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12:1358-1367.
12. Gelbke HP, Knuppen R. 1976. The excretion of five different 2-hydroxyoestrogen monomethyl ethers in human pregnancy urine. J Steroid Biochem 7:457-463.
13. Gingery A, Bradley E, Shaw A, Oursler MJ. 2003. Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival. J Cell Biochem 89:165-179.
14. Heaney RP, Recker RR, Saville PD. 1978. Menopausal changes in bone remodeling. J Lab Clin Med 92:964-970.
15. Hulley SB, Grady D. 2004. The WHI estrogen-alone trial-Do things look any better? [comment]. JAMA 291:1769-1771.
16. Kashii Y, Giorda R, Herberman RB, Whiteside TL, Vujanovic NL. 1999. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J Immunol 163:5358-5366.
17. Katagiri T, Takahashi N. 2002. Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis 8:147-159.
18. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. 1999. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med 189:1451-1460.
19. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. 1997. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57:81-86.
20. Kumar AP, Garcia GE, Orsborn J, Levin VA, Slaga TJ. 2003. 2-Methoxyestradiol interferes with NF kappa B transcriptional activity in primitive neuroectodermal brain tumors: Implications for management. Carcinogenesis 24:209-216.
21. LaVallee TM, Zhan XH, Herbstritt CJ, Kough EC, Green SJ, Pribluda VS. 2002. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res 62:3691-3697.
22. LaVallee TM, Zhan XH, Johnson MS, Herbstritt CJ, Swartz G, Williams MS, Hembrough WA, Green SJ, Pribluda VS. 2003. 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res 63:468-475.
23. Lee SE, Chung WJ, Kwak HB, Chung CH, Kwack KB, Lee ZH, Kim HH. 2001. Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK. J Biol Chem 276:49343-49349.
24. Lin HL, Liu TY, Wu CW, Chi CW. 2001. 2-Methoxyestradiol-induced caspase-3 activation and apoptosis occurs through G(2)/M arrest dependent and independent pathways in gastric carcinoma cells. Cancer 92:500-509.
25. Lotinun S, Westerlind KC, Turner RT. 2001. Tissue-selective effects of continuous release of 2-hydroxyestrone and 16alpha-hydroxyestrone on bone, uterus and mammary gland in ovariectomized growing rats. J Endocrinol 170:165-174.
26. Lu G, Janjic BM, Janjic J, Whiteside TL, Storkus WJ, Vujanovic NL. 2002. Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand. J Immunol 168:1831-1839.
27. Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ. 1998. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 13:1668-1678.
28. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P. 2003. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3:363-375.
29. Manolagas SC. 1995. Role of cytokines in bone resorption. Bone 17:63S-67S.
30. Maran A, Zhang M, Kennedy AM, Sibonga JD, Rickard DJ, Spelsberg TC, Turner RT. 2002. 2-Methoxyestradiol induces interferon gene expression and apoptosis in osteosarcoma cells. Bone 30:393-398.
31. Mukhopadhyay T, Roth JA. 1997. Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene 14:379-384.
32. Mukhopadhyay T, Roth JA. 1998. Superinduction of wild-type p53 protein after 2-methoxyestradiol treatment of Ad5p53-transduced cells induces tumor cell apoptosis. Oncogene 17:241-246.
33. Mundy GR, Boyce B, Hughes D, Wright K, Bonewald L, Dallas S, Harris S, Ghosh-Choudhury N, Chen D, Dunstan C. 1995. The effects of cytokines and growth factors on osteoblastic cells. Bone 17:71S-75S.
34. Pribluda VS, Gubish ER, Lavallee TM, Treston A, Swartz GM, Green SJ. 2000. 2-Methoxyestradiol: An endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev 19:173-179.
35. Richelson LS, Wahner HW, Melton LJ III, Riggs BL. 1984. Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med 311:1273-1275.
36. Ricker JL, Chen Z, Yang XP, Pribluda VS, Swartz GM, Van Waes C. 2004. 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin Cancer Res 10:8665-8673.
37. Riggs BL. 2000. The mechanisms of estrogen regulation of bone resorption [comment]. J Clin Invest 106:1203-1204.
38. Robinson JA, Waters KM, Turner RT, Spelsberg TC. 2000. Direct action of naturally occurring estrogen metabolites on human osteoblastic cells. J Bone Miner Res 15:499-506.
39. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC. 2000. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88: 2961-2978.
40. Roodman GD. 1999. Cell biology of the osteoclast. Exp Hematol 27:1229-1241.
41. Schumacher G, Kataoka M, Roth JA, Mukhopadhyay T. 1999. Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res 5: 493-499.
42. Seegers JC, Lottering ML, Grobler CJ, van Papendorp DH, Habbersett RC, Shou Y, Lehnert BE. 1997. The mammalian metabolite, 2-methoxyestradiol, affects P53 levels and apoptosis induction in transformed cells but not in normal cells. J Steroid Biochem Mol Biol 62:253-267.
43. Sells Galvin RJ, Gatlin CL, Horn JW, Fuson TR. 1999. TGF-beta enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF. Biochem Biophys Res Commun 265:233-239.
44. Sibonga JD, Sommer U, Turner RT. 2002. Evidence that 2-methoxyestradiol suppresses proliferation and accelerates apoptosis in normal rat growth plate chondrocytes. J Cancer Res Clin Oncol 128:477-483.
45. Sibonga JD, Lotinun S, Evans GL, Pribluda VS, Green SJ, Turner RT. 2003. Dose-response effects of 2-methoxyestradiol on estrogen target tissues in the ovariectomized rat. Endocrinology 144:785-792.
46. Suparto IH, Williams JK, Cline JM, Anthony MS, Fox JL. 2003. Contrasting effects of two hormone replacement therapies on the cardiovascular and mammary gland outcomes in surgically postmenopausal monkeys. Am J Obstet Gynecol 188:1132-1140.
47. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T. 2000. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma [comment]. Nature 408:600-605.
48. Takayanagi H, Kim S, Taniguchi T. 2002. Signaling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis Res 4 (Suppl 3):S227-S232.
49. Turner RT, Evans GL. 2000. 2-Methoxyestradiol inhibits longitudinal bone growth in normal female rats. Calcif Tissue Int 66:465-469.
50. Ware CF, Van Arsdale S, Van Arsdale TL. 1996. Apoptosis mediated by the TNF-related cytokine and receptor families. J Cell Biochem 60:47-55.
51. Yue TL, Wang X, Louden CS, Gupta S, Pillarisetti K, Gu JL, Hart TK, Lysko PG, Feuerstein GZ. 1997. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: Possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol Pharmacol 51:951-962.
52. Zhu BT, Conney AH. 1998. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 58:2269-2277.